Hydrochlorothiazide, losartan (Hytenza Co)
Hydrochlorothiazide, losartan
Abex Pharmaceutica (Pty) Ltd
Registration
- Applicant
- Abex Pharmaceutica (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Hytenza co 50/12,5 EACH TABLET CONTAINS: HYDROCHLOROTHIAZIDE 12,5 mg , LOSARTAN POTASSIUM 50,0 mg | 50/12,5 | 43080643/7.1.3/0806 | Registered | Not determined | None |
| Hytenza co 100/25 Each Tablet Contains: Losartan Potassium 100,0 mg & hydrochlorothiazide 25,0 mg | 100/25 | 43080743/7.1.3/0807 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Hydrochlorothiazide
Consolidated Schedules 06 July 2026, line 3721
S3: Losartan
Consolidated Schedules 06 July 2026, line 3908
S3: Potassium
- when intended for intravenous infusion or for injection;
- except when contained in oral rehydration preparations; (S0)
- except in oral preparations or mixtures containing more than 20 millimoles (1500mg) of potassium per 24 hours. (S2)
Consolidated Schedules 06 July 2026, lines 4148 to 4153
S2: Potassium
- in oral preparations or mixtures containing more than 20 millimoles (1500mg) of potassium per 24 hours;
- except when intended for intravenous infusion or for injection; (S3) and
- except when contained in oral rehydration preparations. (S0)
Consolidated Schedules 06 July 2026, lines 2563 to 2569
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.